new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




  

Signal Pharmaceuticals Llc patents

Recent patent applications related to Signal Pharmaceuticals Llc. Signal Pharmaceuticals Llc is listed as an Agent/Assignee. Note: Signal Pharmaceuticals Llc may have other listings under different names/spellings. We're not affiliated with Signal Pharmaceuticals Llc, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "S" | Signal Pharmaceuticals Llc-related inventors




Date Signal Pharmaceuticals Llc patents (updated weekly) - BOOKMARK this page
03/09/17Treatment of cancer with dihydropyrazino-pyrazines
02/16/17Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
02/16/17Solid forms comprising 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof
02/16/17Methods for measurement of inhibition of c-jun n-terminal kinase in skin
02/02/17Treatment of cancer with tor kinase inhibitors
12/08/16Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
11/03/16Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
09/08/16Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
09/01/16Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
06/16/16Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
06/16/16Methods for measurement of inhibition of c-jun n-terminal kinase in skin
04/07/16Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
02/11/16Haloaryl substituted aminopurines, compositions thereof,and methods of treatment therewith
01/28/16Pyrazino[2,3-b]pyrazine mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway
01/14/16Treatment of cancer with tor kinase inhibitors
01/14/16Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
01/14/16Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
12/17/15Inhibition of phosphorylation of pras40, gsk3-beta or p70s6k1 as a marker for tor kinase inhibitory activity
11/26/15Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
10/22/15Methods for treating cancer using tor kinase inhibitor combination therapy
10/22/15Methods for treating cancer using tor kinase inhibitor combination therapy
10/22/15Solid forms comprising 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof
10/22/15Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof
10/22/15Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
09/03/15Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
07/30/15Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
06/25/15Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
04/09/15Treatment of cancer characterized by gene mutations
02/19/15Pyrazino[2,3-b]pyrazine mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway
12/04/14Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
10/23/14Treatment of cancer with dihydropyrazino-pyrazines
10/23/14Treatment of cancer with dihydropyrazino-pyrazines
10/23/14Methods for treating cancer using tor kinase inhibitor combination therapy
10/23/14Methods for treating cancer using tor kinase inhibitor combination therapy
10/23/14Methods for treating cancer using tor kinase inhibitor combination therapy
10/23/14Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
10/23/14Treatment of cancer with dihydropyrazino-pyrazines
10/23/14Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
10/23/14Methods for treating cancer using tor kinase inhibitor combination therapy
07/24/14Haloaryl substituted aminopurines, compositions thereof,and methods of treatment therewith
06/05/14Methods of synthesis and purification of heteroaryl compounds
04/24/14Treatment of cancer with tor kinase inhibitors
04/24/14Inhibition of phosphorylation of pras40, gsk3-beta or p70s6k1 as a marker for tor kinase inhibitory activity
04/03/14Pharmaceutical formulations of a substituted diaminopurine
10/31/13Pyrazino[2,3-b]pyrazine mtor kinase inhibitors for oncology indications and diseases associated with the mtor/pi3k/akt pathway
09/19/13Treatment of cancer with tor kinase inhibitors
09/19/13Treatment of cancer with tor kinase inhibitors
09/19/13Treatment of cancer with tor kinase inhibitors
09/19/13Treatment of cancer with tor kinase inhibitors
09/19/13Methods of synthesis and purification of heteroaryl compounds
08/29/13Methods for treating cancer using tor kinase inhibitor combination therapy
08/29/13Haloaryl substituted aminopurines, compositions thereof,and methods of treatment therewith
06/20/13Identification of gene expression as a predictive biomarker for lkb1 status
06/06/13Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
04/25/13Treatment of cancer with tor kinase inhibitors
10/06/11Methods of treatment comprising the administration of heteroaryl compounds
09/15/11Methods of treatment using heteroaryl compounds and compositions thereof
09/30/10Methods of modulating inflammatory cell recruitment and gene expression using haloaryl substituted aminopurines
12/17/09Methods of treatment comprising the administration of haloaryl substituted aminopurines or compositions thereof







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Signal Pharmaceuticals Llc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Signal Pharmaceuticals Llc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';